Academic Reference Archive：rasH2

1984

• Sekiya T, Fushimi M, Hori H, Hirohashi S, Nishimura S, Sugimura T.
  Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient.
  Proc Natl Acad Sci USA. 1984; 81(15):4771-5. [PMID: 6087347]

1985

• Sekiya T, Prassolov VS, Fushimi M, Nishimura S.
  Transforming activity of the c-Ha-ras oncogene having two point mutations in codons 12 and 61.
  Jpn J Cancer Res. 1985; 76(9): 851-5. [PMID: 3932284]

1990

• Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, Izawa M, Sekiya T, Nishimura S, Katsuki M.
  Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes.
  Oncogene. 1990; 5(8): 1195-200. [PMID: 2202951]

1992

• Ando K, Saitoh A, Hino O, Takahashi R, Kimura M, Katsuki M.
  Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes.
  Cancer Res. 1992; 52(4): 978-82. [PMID: 1737360]

• Izawa M, Takayama S, Shindo-Okada N, Doi S, Kimura M, Katsuki M, Nishimura S.
  Inhibition of chemical carcinogenesis in vivo by azatyrosine.
  Cancer Res. 1992; 52(6): 1628-30. [PMID: 1540971]

1994

• Doi ST, Kimura M, Katsuki M.
  Site-specific mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissue-specific tumors in mice.
  Jpn J Cancer Res. 1994; 85(8): 801-7. [PMID: 7928625]

• Tsunematsu S, Saito H, Kagawa T, Morizane T, Hata J, Nakamura T, Ishii H, Tsuchiya M, Nomura T, Katsuki M.
  Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c-H-ras proto-oncogene without mutations.
  Int J Cancer. 1994; 59(4): 554-9. [PMID: 7960226]

1996

• Inoue R, Ushijima T, Katami M, Kushida H, Wakabayashi K, Sato H, Asamoto M, Katsuki M, Sugimura T, Nagao M.
  Rare activation of the human c-Ha-ras transgene of mice in hemangioendothelial sarcomas and liver tumors induced by Glu-P-1.
  Jpn J Cancer Res. 1996; 87(6): 583-8. [PMID: 8766521]

• Ogawa K, Imaida K, Masui T, Kawabe M, Hasegawa R, Kato K, Ito N, Shirai T.
  Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant forms of the human c-Ha-ras transgene.
  Carcinogenesis. 1996; 17(2): 341-5. [PMID: 8625461]

• Yamamoto S, Mitsumori K, Kodama Y, Matsunuma N, Manabe S, Okamiya H, Suzuki H, Fukuda T, Sakamaki Y, Sunaga M, Nomura G, Hioki K, Wakana S, Nomura T, Hayashi Y.
  Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
  Carcinogenesis. 1996; 17(11): 2455-61. [PMID: 8968063]

1997

• Mitsumori K, Wakana S, Yamamoto S, Kodama Y, Yasuhara K, Nomura T, Hayashi Y, Maronpot RR.
  Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors.
  Mol Carcinog. 1997; 20(3): 298-307. [PMID: 9397190]

• Tsunematsu S, Saito H, Sato R, Morizane T, Ishii H.
  Role of H-ras gene in chronic liver damage in mice. By using transgenic mice carrying a human C-H-ras proto-oncogene without mutations.
  Biochem Mol Biol Int. 1997; 42(2): 371-9. [PMID: 9238536]

• Tsunematsu S, Saito H, Tada S, Ebinuma H, Tsuchiya M, Kumagai N, Morizane T, Nomura T, Ishii H.
  Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene.
  J Gastroenterol Hepatol. 1997; 12(4): 319-24. [PMID: 9195373]

• Yamamoto S, Hayashi Y, Mitsumori K, Nomura T.
  Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene.
  Lab Anim Sci. 1997; 47(2): 121-6. [PMID: 9150488]

1998

• Hayashi S, Mori I, Nonoyama T, Mitsumori K.
  Point mutations of the c-H-ras gene in spontaneous liver tumors of transgenic mice carrying the human c-H-ras gene.
  Toxicol Pathol. 1998; 26(4): 556-61. [PMID: 9715515]

• Mitsumori K, Yasuhara K, Mori I, Hayashi S, Shimo T, Onodera H, Nomura T, Hayashi Y.
  Pulmonary fibrosis caused by N-methyl-N-nitrosourethane inhibits lung tumorigenesis by urethane in transgenic mice carrying the human prototype c-Ha-ras gene.
  Cancer Lett. 1998; 129(2): 181-90. [PMID: 9719460]

• Mitsumori K, Koizumi H, Nomura T, Yamamoto S.
  Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
  Toxicol Pathol. 1998; 26(4): 520-31. [PMID: 9715511]

• Narushima S, Itoh K, Mitsuoka T, Nakayama H, Itoh T, Hioki K, Nomura T.
  Effect of mouse intestinal bacteria on incidence of colorectal tumors induced by 1,2-dimethylhydrazine injection in gnotobiotic transgenic mice harboring human prototype c-Ha-ras genes.
  Exp Anim. 1998; 47(2): 111-7. [PMID: 9606421]

• Yamamoto S, Urano K, Nomura T.
  Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
  Toxicol Lett. 1998; 102-103: 473-8. [PMID: 10022298]

• Yamamoto S, Urano K, Koizumi H, Wakana S, Hioki K, Mitsumori K, Kurokawa Y, Hayashi Y, Nomura T.
  Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
  Environ Health Perspect. 1998; 106 Suppl 1: 57-69. [PMID: 9539005]

2000

• Gulezian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, Robinson D, Storer R, Tennant R, Ward JM, Neumann DA.
  Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
  Toxicol Pathol. 2000; 28(3): 482-99. [PMID: 10862569]

• Katsutani N, Sekido T, Aoki T, Sagami F.
  Hepatic drug metabolizing enzymes induced by clofibrate in rasH2 mice.
  Toxicol Lett. 2000; 115(3): 223-9. [PMID: 10814892]

• Kobayashi K, Sano F, Mutai M, Sugimoto J.
  Glomerulonephritis with fibrillary deposition in a transgenic mouse carrying the human prototype c-Ha-ras gene (rasH2 mouse).
  Toxicol Pathol. 2000; 28(2): 359-62. [PMID: 10805155]

• Koujitani T, Yasuhara K, Usui T, Nomura T, Onodera H, Takagi H, Hirose M, Mitsumori K.
  Lack of susceptibility of transgenic mice carrying the human c-Ha-ras proto-oncogene (rasH2 mice) to phenolphthalein in a 6-month carcinogenicity study.
  Cancer Lett. 2000; 152(2): 211-6. [PMID: 10773414]

• Maronpot RR, Mitsumori K, Mann P, Takaoka M, Yamamoto S, Usui T, Okamiya H, Nishikawa S, Nomura T.
  Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model.
  Toxicology. 2000; 146(2-3): 149-59. [PMID: 10814847]

• Mori I, Yasuhara K, Hayashi SM, Nonoyama T, Nomura T, Mitsumori K.
  Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototype c-Ha-ras gene.
  Cancer Lett. 2000; 153(1-2): 199-209. [PMID: 10779650]

• Ohno K, Narushima S, Takeuchi S, Itoh K, Mitsuoka T, Nakayama H, Itoh T, Hioki K, Nomura T.
  Inhibitory effect of apple pectin and culture condensate of Bifidobacterium longum on colorectal tumors induced by 1,2-dimethylhydrazine in transgenic mice harboring human prototype c-Ha-ras genes.
  Exp Anim. 2000; 49(4): 305-7. [PMID: 11109558]

• Storer RD.
  Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals-scientific perspective.
  Toxicol Lett. 2000; 112-113: 557-66. [PMID: 10720780]

• Takegawa K, Mitsumori K, Yasuhara K, Moriyasu M, Sakamori M, Onodera H, Hirose M, Nomura T.
  A mechanistic study of ovarian carcinogenesis induced by nitrofurazone using rasH2 mice.
  Toxicol Pathol. 2000; 28(5): 649-55. [PMID: 11026599]

2001

• Birumachi J, Suzuki AK, Itoh K, Hioki K, Maruyama C, Ohnishi Y.
  Diesel exhaust-induced airway hyperresponsiveness in c-Ha-ras transgenic mice.
  Toxicology. 2001; 163(2-3): 145-52. [PMID: 11516524]

• Maruyama C, Tomisawa M, Wakana S, Yamazaki H, Kijima H, Suemizu H, Ohnishi Y, Urano K, Hioki K, Usui T, Nakamura M, Tsuchida T, Mitsumori K, Nomura T, Tamaoki N, Ueyama Y.
  Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice.
  Oncol Rep. 2001; 8(2): 233-7. [PMID: 11182032]

• Mori I, Yasuhara K, Hayashi SM, Nonoyama T, Nomura T, Yanai T, Masegi T, Mitsumori K.
  Aberrant expression of cyclin D1 in pulmonary proliferative lesions induced by high doses of urethane in transgenic mice carrying the human prototype c-H-ras gene.
  J Vet Med Sci. 2001; 63(3): 261-8. [PMID: 11307925]

• Ohnishi Y, Arai T, Koshirakawa M, Horii N, Nakajo S, Urano K, Usui T, Tamaoki N, Ueyama Y.
  Induction of drug metabolism-related enzymes by methylcholanthrene and phenobarbital in transgenic mice carrying human prototype c-Ha-ras gene and their wild type littermates.
  Exp Anim. 2001; 50(1): 33-9. [PMID: 11326421]

• Ohno K, Narushima S, Takeuchi S, Itoh K, Itoh T, Hioki K, Nomura T.
  Effect of bacterial metabolism in the intestine on colorectal tumors induced by 1,2-dimethylhydrazine in transgenic mice harboring human prototype c-Ha-ras genes.
  J Exp Clin Cancer Res. 2001; 20(1): 51-6. [PMID: 11370830]

• Koujitani T, Yasuhara K, Tamura T, Onodera H, Takagi H, Takizawa T, Hirose M, Hayashi Y, Mitsumori K.
  Lack of modifying effects of eugenol on development of lung proliferative lesions induced by urethane in transgenic mice carrying the human prototype c-Ha-ras gene.
  J Toxicol Sci. 2001; 26(3): 129-39. [PMID: 11552296]

• Toyosawa K, Okimoto K, Kobayashi I, Kijima K, Kikawa E, Kohchi M, Koujitani T, Tanaka K, Matsuoka N.
  Toxicol Pathol. Di(2-ethylhexyl) phthalate induces hepatocellular adenoma in transgenic mice carrying a human prototype c-Ha-ras gene in a 26-week carcinogenicity study.
  Toxicol Pathol. 2001; 29(4): 458-66. [PMID: 11560251]

• Umemura T, Kodama Y, Hioki K, Inoue T, Nomura T, Kurokawa Y.
  Butylhydroxytoluene (BHT) increases susceptibility of transgenic rasH2 mice to lung carcinogenesis.
  J Cancer Res Clin Oncol. 2001; 127(10): 583-90. [PMID: 11599794]

• Omenn GS.
  Assessment of human cancer risk: challenges for alternative approaches.
  Toxicol Pathol. 2001; 29 Suppl: 5-12. [PMID: 11695561]

• Robinson DE, and MacDonald JS.
  Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
  Toxicol Pathol. 2001; 29 Suppl: 13-9. [PMID: 11695549]

• Popp JA.
  Criteria for the evaluation of studies in transgenic models.
  Toxicol Pathol. 2001; 29 Suppl: 20-3. [PMID: 11695558]

• French J, Storer RD, and Donehower LA.
  The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
  Toxicol Pathol. 2001; 29 Suppl: 24-9. [PMID: 11695559]

• Storer RD, French JE, Haseman J, Hajian G, LeGrand EK, Long GG, Mixson LA, Ochoa R, Sagartz JE, Soper KA.
  P53+/- hemizygous knockout mouse: overview of available data.
  Toxicol Pathol. 2001; 29 Suppl: 30-50. [PMID: 11695560]

• Tamaoki N.
  The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
  Toxicol Pathol. 2001; 29 Suppl: 81-9. [PMID: 11695564]

• Usui T, Mutai M, Hisada S, Takoaka M, Soper KA, McCullough B, Alden C.
  CB6F1-rasH2 mouse: overview of available data.
  Toxicol Pathol. 2001; 29 Suppl: 90-108. [PMID: 11695565]

• Ariyoshi N, Imaoka S, Nakayama K, Takahashi Y, Fujita K, Funae Y, Kamataki T.
  Comparison of the levels of enzymes involved in drug metabolism between transgenic or gene-knockout and the parental mice.
  Toxicol Pathol. 2001; 29 Suppl: 161-72. [PMID: 11695553]

• Goodman JI.
  A perspective on current and future uses of alternative models for carcinogenicity testing.
  Toxicol Pathol. 2001; 29 Suppl: 173-6. [PMID: 11695554]

• Ashby J.
  Expectations for transgenic rodent cancer bioassay models.
  Toxicol Pathol. 2001; 29 Suppl: 177-82. [PMID: 11695555]

• Cohen SM.
  Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
  Toxicol Pathol. 2001; 29 Suppl: 183-90. [PMID: 11695556]

• Pettit SD.
  Panel discussion on the application of alternative models to cancer risk assessment.
  Toxicol Pathol. 2001; 29 Suppl: 191-5. [PMID: 11695557]

• 林 裕三.
  ICHを契機とした前臨床試験の進歩 –発がん性の短期代替法を中心に-.
  実中研レポート. 2001/6: 1-9.

• 玉置憲一.
  短期発がん性試験におけるrasH2マウスの遺伝子的品質と発癌機構.
  実中研レポート. 2001/6: 10-26.

• 臼居敏仁.
  がん原性短期大代替試験の国際共同研究の成果 –CB6F1-raH2マウスの検証結果-.
  実中研レポート. 2001/6: 27-31.

• 玉置憲一.
  医薬品短期代替発がん試験法ワークショップから –ILSI/HESI Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing (November 1-3,2000)から-.
  実中研レポート. 2001/6: 32-8.

• Torii M, Itoh F, Yabuuchi K, Ohno K, Kominami G, Hirano K, Tasaki T, Nara H.
  Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
  J Toxicol Sci. 2001; 26(2): 61-73. [PMID: 11429969]

2002

• 木村 穣, 勝木 元也.
  ヒトras遺伝子導入トランスジェニックマウス(1) -その樹立と生物学的意義-. ヒト型モデル動物.
  シュプリンガー・フェアラーク東京, 2002: 113-20.

• 玉置 憲一, 臼居 敏仁.
  ヒトras遺伝子導入トランスジェニックマウス(2) -医薬品短期発がん試験への応用-. ヒト型モデル動物.
  シュプリンガー・フェアラーク東京, 2002: 121-9.

• Adachi T, Kuwamura Y, Fujiwara T, Tanimoto N, Nishimura T, Koguchi A, Kobayashi K, Sasaki Y, Yamaguchi C, Honda T, Kawashima K, Yuasa H, Yamamura T, Inui T.
  Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.
  J Toxicol Sci. 2002; 27: 147-63.

• Aoki T, Imai T, Ando T, Dodo T, Kerns WD, Motooka S, Tsukidate K.
  Effects of Clofibrate in the CB6F1-TgHras2 Mice.
  J Toxicol Pathol. 2002; 15: 111-8.

• Arai T, Ogawa T, Nakamura M, Hosoya Masaru, Ohnishi Y.
  Changes in Hepatic Enzyme Activities in Transgenic Mice Carrying Human Prototype c-Ha-ras Gene Treated with Diethylnitrosamine.
  J Vet Med Sci. 2002; 64(11): 1065-7.

• Imaoka M, Kashida Y, Watanabe T, Ueda M, Onodera H, Hirose M, Mitsumori K.
  Tumor Promoting Effect of Phenolphthalein on Development of Lung Tumors Induced by N-ethyl-N-nitrosourea in Transgenic Mice Carrying Human Prototype c-Ha-ras Gene.
  J Vet Med Sci. 2002; 64(6): 489-93.

• Itoh J, Kashida Y, Watanabe T, Yasuhara K, Takizawa T, Ueda M, Yoshimura H, Hirose Masao, Mitsumori K.
  Lack of Modifying Effect of Glycerol in Pulmonary Carcinogenesis in rasH2 Mice Induced by Urethane or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
  J Toxicol Pathol. 2002; 15: 215-20.

• Mitsumori K.
  Evaluation on carcinogenicity of chemicals using transgenic mice.
  Toxicology. 2002; 181-182: 241-4. [PMID: 12505318]

• Morton D, Alden CL, Roth AJ, Usui T.
  The Tg rasH2 mouse in cancer hazard identification.
  Toxicol Pathol. 2002; 30(1): 139-46. [PMID: 11890467]

• Suemizu H, Muguruma K, Maruyama C, Tomisawa M, Kimura M, Hioki K, Shimozawa N, Ohnishi Y, Tamaoki N, Nomura T.
  Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing.
  Mol Carcinog. 2002; 34(1): 1-9. [PMID: 12112317]

• Umemura T, Kodama Y, Hioki K, Nomura T, Nishikawa A, Hirose M, Kurokawa Y.
  The mouse rasH2/BHT model as an in vivo rapid assay for lung carcinogens.
  Jpn J Cancer Res. 2002; 93(8): 861-6. [PMID: 12716462]

• Watanabe T, Ueda M, Yasuhara K, Onodera H, Hirose M, Mitsumori K.
  Modifying Effects of Genistein, 4-Nonylphenol and Methoxychlor on N - ethyl - N - nitrosourea-induced Uterine Carcinogenesis in RasH2 Transgenic Mice Harboring a Human Prototype C-Ha-ras Gene.
  J Toxicol Pathol. 2002; 15: 145-51.

• Imai T, Yasuhara K, Tamura T, Takizawa T, Ueda M, Hirose M, Mitsumori K.
  Inhibitory effects of cinnamaldehyde on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung carcinogenesis in rasH2 mice
  Cancer Lett. 2002; 175(1): 9-16. [PMID: 11734331]

• Watanabe T, Kashida Y, Yasuhara K, Koujitani T, Hirose M, Mitsumori K.
  Rapid induction of uterine endometrial proliferative lesions in transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) given a single intraperitoneal injection of N-ethyl-N-nitrosourea.
  Cancer Lett. 2002; 188(1-2): 39-46. [PMID: 12406546]

• Tsuchiya T, Kobayashi K, Sakairi T, Goto K, Okada M, Sano F, Sugimoto J, Morohashi T, Usui T, Mutai M.
  Skeletal myopathy in transgenic mice carrying human prototype c-Ha-ras gene.
  Toxicol Pathol. 2002; 30(4): 501-6. [PMID: 12187941]

2003

• Kanno H, Tanakamaru Z, Ishimura Y, Kandori H, Yamasaki H, Sasaki S.
  Historical Background Data in CB6F1-Tg-rasH2 Mice and CB6F1-nonTg-rasH2 Mice over a 26-Week Experimental Period.
  J Toxicol Pathol. 2003; 16: 267-74.

• Minemura Y, Kashida Y, Watanabe T, Yasuhara K, Takizawa T, Hirose M, Mitsumori K.
  Modifying Effects of 2,6-Dimethylaniline on Nasal Carcinogenesis in RasH2 Mice Initiated with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone.
  J Toxicol Pathol. 2003; 16: 41-7.

• Mitsumori K.
  Possible mechanism on enhanced carcinogenesis of genotoxic carcinogens and unsolved mechanisms on lesser carcinogenic susceptibility to some carcinogens in rasH2 mice.
  J Toxicol Sci. 2003; 28(5): 371-83. [PMID: 14746341]

• Pritchard JB, French JE, Davis BJ, Haseman JK.
  The role of transgenic mouse models in carcinogen identification.
  Environ Health Perspect. 2003; 111(4): 444-54. [PMID: 12676597]

• Storer RD, French JE, Donehower LA, Gulezian D, Mitsumori K, Recio L, Schiestl RH, Sistare FD, Tamaoki N, Usui T, van Steeg H; IWGT Working Group.
  Transgenic tumor models for carcinogen identification: the heterozygous Trp53-deficient and RasH2 mouse lines.
  Mutat Res. 2003; 540: 165-76. [PMID: 14550500]

• Takahashi A, Kashida Y, Watanabe T, Yasuhara K, Takizawa T, Hirose M, Yoshimura H, Mitsumori K.
  Lack of Modifying Effects of 2,6-Dimethylaniline on Lung Carcinogenesis in Transgenic Mice Carrying Human Prototype c-Ha-ras Gene Initiated with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone.
  J Toxicol Pathol. 2003; 16: 25-31.

• Takaoka M, Sehata S, Maejima T, Imai T, Torii M, Satoh H, Toyosawa K, Tanakamaru ZY, Adachi T, Hisada S, Ueda M, Ogasawara H, Matsumoto M, Kobayashi K, Mutai M, Usui T.
  Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
  Toxicol Pathol. 2003; 31(2): 191-9. [PMID: 12696579]

• Tomisawa M, Suemizu H, Ohnishi Y, Maruyama C, Urano K, Usui T, Yasuhara K, Tamaoki N, Mitsumori K.
  Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice.
  Toxicol Lett. 2003; 142(1-2): 111-7. [PMID: 12765245]

• Toyosawa K, Tanaka K, Imai T, Yasuhara K, Koujitani T, Hirose M, Mitsumori K.
  Mutation and overexpression of the transgene in ethylnitrosourea-induced tumors in mice carrying a human prototype c-Ha-ras gene.
  Toxicol Pathol. 2003; 31(5): 491-5. [PMID: 14692617]

• Watanabe T, Kashida Y, Ueda M, Onodera H, Takizawa T, Hirose M, Mitsumori K.
  Inhibition by ethinylestradiol of N - ethyl - N - nitrosourea - initiated uterine carcinogenesis in transgenic mice carrying a human prototype C-Ha-ras gene (rasH2 mice).
  Toxicol Pathol. 2003; 31(5): 496-505. [PMID: 14692618]

• Toyosawa K, Okugawa K, Teranishi Y, Tanaka K, Matsuoka N.
  Overexpression of the peroxisome proliferator activated receptor alpha or the human c-Ha-ras transgene is not involved in tumorigenesis induced by di(2-ethylhexyl) phthalate in rasH2 mice.
  Cancer Lett. 2003; 192(2): 199-203. [PMID: 12668284]

• Hirakawa K, Midorikawa K, Oikawa S, Kawanishi S.
  Carcinogenic semicarbazide induces sequence-specific DNA damage through the generation of reactive oxygen species and the derived organic radicals.
  Mutat Res. 2003; 536(1-2): 91-101. [PMID: 12694749]

2004

• Curtin GM, Higuchi MA, Ayres PH, Swauger JE, Mosberg AT.
  Lung tumorigenicity in A/J and rasH2 transgenic mice following mainstream tobacco smoke inhalation.
  Toxicol Sci. 2004; 81(1): 26-34. [PMID: 15159525]

• Imaoka M, Satoh H, Furuhama K.
  Lack of Carcinogenicity of Reserpine in Transgenic Mice Carrying a Human Prototype c-Ha-ras Gene (RasH2 Mice).
  J Toxicol Pathol. 2004; 17(2): 95-103.

• MacDonald J, French JE, Gerson RJ, Goodman J, Inoue T, Jacobs A, Kasper P, Keller D, Lavin A, Long G, McCullough B, Sistare FD, Storer R, van der Laan JW.
  The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
  Toxicol Sci. 2004; 77(2): 188-94. [PMID: 14657512]

• Morton D, Sellers RS, Furst SM, Hawley KD, May JR.
  Effect of oral gavage dosing regimens in female Tg rasH2 transgenic mice.
  Toxicol Pathol. 2004; 32(4): 413-7. [PMID: 15204964]

• Okamura M, Moto M, Kashida Y, Machida N, Mitsumori K.
  Carcinogenic susceptibility to N-bis (2-hydroxypropyl) nitrosamine (DHPN) in rasH2 mice.
  Toxicol Pathol. 2004; 32(4): 474-81. [PMID: 15223773]

• Okamura M, Sumida K, Muto T, Kashida Y, Machida N, Watanabe T, Mitsumori K.
  Analysis of gene expression profiles of forestomach tumors in rasH2 mice initiated with N-ethyl-N-nitrosourea.
  Arch Toxicol. 2004; 78(12): 688-96. [PMID: 15249993]

• Suemizu H, Kito-Maruyama C, Sotomaru Y, Ogura T, Hioki K, Ohnishi Y, Tamaoki N.
  PCR method for genotyping and zygosity-testing of RasH2 transgenic mice.
  Exp Anim. 2004; 53(5): 463-6. [PMID: 15516796]

• Watanabe T, Sumida K, Muto T, Kashida Y, Watanabe T, Mitsumori K.
  Analysis of Gene Expression Profile on Uterine Tumorigenesis Initiated with N-ethyl-N-nitrosourea and Inhibited by Ethinylestradiol in rasH2 Mice.
  J Toxicol Pathol. 2004; 17: 155-64.

2005

• Matsuo S, Okamura M, Takizawa T, Imai T, Mitsumori K, Hirose M.
  Lack of Modifying Effects of Combined Treatment of t-butylhydroquinone and Sodium Nitrite on Forestomach Carcinogenesis in rasH2 Mice Initiated with N-ethyl-N-nitrosourea.
  J Toxicol Pathol. 2005; 18: 111-6.

• Nesfield SR, Clarke CJ, Hoivik DJ, Miller RT, Allen JS, Selinger K, Santostefano MJ.
  Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
  Int J Toxicol. 2005; 24(5):301-11. [PMID: 16257850]

• Ozaki M, Ozaki K, Watanabe T, Uwagawa S, Okuno Y, Shirai T.
  Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains.
  Toxicol Pathol. 2005; 33(2): 267-71. [PMID: 15902970]

• Tsuchiya T, Okada M, Sakairi T, Sano F, Sugimoto J, Takagi S.
  Histopathological characterization of the skeletal myopathy in rasH2 mice carrying human prototype c-Ha-ras gene.
  J Vet Med Sci. 2005; 67(5): 481-9. [PMID: 15942132]

• Yamazaki M, Moto M, Takizawa T, Kashida Y, Imai T, Mitsumori K, Hirose M.
  Tumorigenic Susceptibility of Catechol on the Gastric Mucosa in rasH2 Mice.
  J Toxicol Pathol. 2005; 18: 1-5.

2006

• Muto S, Katsuki M, Horie S.
  Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis.
  Cancer Sci. 2006; 97(9): 842-7. [PMID: 16805855]

• Okamura M, Unami A, Matsumoto M, Oishi Y, Kashida Y, Mitsumori K.
  Gene expression analysis of urethane-induced lung tumors in ras H2 mice.
  Toxicology. 2006; 217(2-3): 129-38. [PMID: 16289808]

• Okamura M, Moto M, Muguruma M, Ito T, Jin M, Kashida Y, Mitsumori K.
  A 26-week carcinogenicity study of 2- amino-3-methylimidazo [4,5-f] quinoline in rasH2 mice.
  Toxicol Pathol. 2006; 34(2): 199-205. [PMID: 16537296]

• Urano K, Suzuki S, Machida K, Sawa N, Eguchi N, Kikuchi K, Fukasawa K, Taguchi F, Usui T.
  Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice.
  J Toxicol Sci. 2006; 31(5): 407-18. [PMID: 17202757]

• Umemura T, Kodama Y, Nishikawa A, Hioki K, Nomura T, Kanki K, Kuroiwa Y, Ishii Y, Kurokawa Y, Hirose M.
  Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model.
  Cancer Lett. 2006; 231(2): 314-8. [PMID: 16399233]

2007

• Okamura M, Unami A, Moto M, Muguruma M, Ito T, Jin M, Oishi Y, Kashida Y, Mitsumori K.
  The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice.
  Cancer Lett. 2007; 245(1-2): 321-30. [PMID: 16530936]

• Jin M, Takahashi M, Moto M, Muguruma M, Ito K, Watanabe K, Kenmochi Y, Kono T, Hasumi K, Mitsumori K.
  Carcinogenic susceptibility of rasH2 mice to troglitazone.
  Arch Toxicol. 2007; 81(12): 883-94. [PMID: 17569031]

• Urano K, Suzuki S, Machida K, Eguchi N, Sawa N, Kikuchi K, Hattori Y, Usui T.
  Examination of Percutaneous Application in a 26-week Carcinogenicity Test in CB6F1-Tg rasH2 Mice.
  J Toxicol Sci. 2007; 32(4): 367-75. [PMID: 17965551]

2008

• Miyamoto S, Yasui Y, Kim M, Sugie S, Murakami A, Ishigamori-Suzuki R, Tanaka T.
  A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies.
  Carcinogenesis. 2008; 29(2): 418-26. [PMID: 18174262]

• Jin M, Matsumoto S, Dewa Y, Nishimura J, Saekusa Y, Hasumi K, Mitsumori K.
  Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane.
  Arch Toxicol. 2008; 82(10): 771-7. [PMID: 18465119]

• Bridges EG, Selden JR, Luo S.
  Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.
  Antimicrob Agents Chemother. 2008; 52(7): 2521-8. [PMID: 18474576]

• Machida K, Urano K, Yoshimura M, Tsutsumi H, Nomura T, Usui T.
  Carcinogenic comparative study on rasH2 mice produced by two breeding facilities.
  J Toxicol Sci. 2008; 33(4): 493-501. [PMID: 18827450]

• Kawai M, Jin M, Nishimura J, Dewa Y, Saegusa Y, Matsumoto S, Taniai E, Shibutani M, Mitsumori K.
  Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice.
  Toxicol Pathol. 2008; 36(7): 950-7. [PMID: 18978307]

• Katoku K, Oshikata T, Kumabe S, Kuwasaki E, Mitsuishi M, Nakahara Y, Hamamura M.
  Epithelial Proliferative Lesions in the Nasal Cavities of c-Ha-ras Transgenic Mice.
  J Toxicol Pathol 2008; 21(3): 193-7. 2009

• Jin M, Saekusa Y, Dewa Y, Nishimura J, Matsumoto S, Shibutani M, Hasumi K, Mitsumori K.
  Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model.
  Arch Toxicol. 2009; 83(2): 173-81. [PMID: 18597072]

2010

• Narushima S, Sakata T, Hioki K, Itoh T, Nomura T, Itoh K.
  Inhibitory effect of yogurt on aberrant crypt foci formation in the rat colon and colorectal tumorigenesis in RasH2 mice.
  Exp Anim. 2010; 59(4): 487-94. [PMID: 20660995]

2011

• Park HJ1, Oh JH, Park SM, Cho JW, Yum YN, Park SN, Yoon DY, Yoon S.
  Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis.
  Arch Toxicol. 2011 Dec;85(12):1627-40. [PMID: 21607683]

2012

• Urano K, Tamaoki N, Nomura T.
  Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science.
  Vet Pathol. 2012 Jan;49(1):16-23. [PMID: 22146850]

• Sagawa Y, Futakuchi M, Xu J, Fukamachi K, Sakai Y, Ikarashi Y, Nishimura T, Suzui M, Tsuda H, Morita A.
  Lack of promoting effect of titanium dioxide particles on chemically-induced skin carcinogenesis in rats and mice.
  J Toxicol Sci. 2012;37(2):317-27. [PMID: 22467022]

• Takanashi S, Hara K, Aoki K, Usui Y, Shimizu M, Haniu H, Ogihara N, Ishigaki N, Nakamura K, Okamoto M, Kobayashi S, Kato H, Sano K, Nishimura N, Tsutsumi H, Machida K, Saito N.
  Carcinogenicity evaluation for the application of carbon nanotubes as biomaterials in rasH2 mice.
  Sci Rep. 2012;2:498. [PMID: 22787556]

2013

• Kawabe M, Urano K, Suguro M, Numano T, Taguchi F, Tsutsumi H, Furukawa F.
  Tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in an ultra-short-term skin carcinogenesis bioassay using rasH2 mice.
  Vet Pathol. 2013 Sep;50(5):903-8. [PMID: 23610217]

2015

• Darbes J, Sistare FD, DeGeorge JJ.
  Regulatory Forum Commentary* Counterpoint: Dose Selection for Tg.rasH2 Mouse Carcinogenicity Studies.
  Toxicol Pathol. 2015 Jul;43(5):621-7. doi: 10.1177/0192623315587722. Epub 2015 Jun 4. [PMID: 26047967]

• Tsuji S, Kuwahara Y, Takagi H, Sugiura M, Nakanishi Y, Wakamatsu M, Tsuritani K, Sato Y.
  Gene expression analysis in the lung of the rasH2 transgenic mouse at week 4 prior to induction of malignant tumor formation by urethane and N-methylolacrylamide.
  J Toxicol Sci. 2015;40(6):685-700. [PMID: 26558449]

2016

• Sano T, Takai Y, Anayama H, Watanabe T, and Fukuda R.
  Accumulation of Mott cells in the spleen in a CB6F1-Tg rasH2 mouse.
  Journal of Toxicologic Pathology Article ID: 2016-0023 [PMID: 27821912]

2017

• Sano T, Watanabe T, Ishimura Y, Anayama H.
  Immunohistochemical characterization of urethane-induced lung tumors in CB6F1-Tg rasH2 mice.
  J Toxicol Pathol. 2017 Apr;30(2):177-181. [PMID: 28458456]

• Suguro M, Numano T, Kawabe M, Doi Y, Imai N, Mera Y, Tamano S.
  Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.
  Toxicol Pathol. 2017 Apr;45(3):427-434. [PMID: 28421967]

• Kuroda H, Kinomoto T, Ogawa S, Kawabe M, Suguro M, Naraoka H, Takamatsu K, Oishi Y.
  Progression process and safety assessment adaptation of endometrial lesions in ENU-induced 2-stage uterine carcinogenicity in a Tg-rasH2 mouse model.
  J Toxicol Pathol. 2018 Jan;31(1):35-41. [PMID: 29479138]

2019

• Nishimura I, Doi Y, Imai N, Kawabe M, Mera Y, Shiina T.
  Carcinogenicity of intermediate frequency magnetic field in Tg.rasH2 mice.
  Bioelectromagnetics. 2019 Apr;40(3):160-169. [PMID: 30875092]

• Yasuno K, Igura S, Yamaguchi Y, Imaoka M, Kai K, Mori K.
  Pathological examination of spontaneous vacuolation of pancreatic acinar cells in mice.
  J Toxicol Pathol. 2019 Apr;32(2):105-109. [PMID: 31092977]

• Fujiwara K, Yazama H, Donishi R, Koyama S, Fukuhara T, Takeuchi H.
  Inhibitory Effects of Glucosylceramide on Tumorigenesis Induced by a Carcinogen in Mice.
  Laryngoscope. 2019 Dec 6. [PMID: 31808958]

• Sobajima A, Haniu H, Nomura H, Tanaka M, Takizawa T, Kamanaka T, Aoki K, Okamoto M, Yoshida K, Sasaki J, Ajima K, Kuroda C, Ishida H, Okano S, Ueda K, Kato H, Saito N.
  Organ accumulation and carcinogenicity of highly dispersed multi-walled carbon nanotubes administered intravenously in transgenic rasH2 mice.
  Int J Nanomedicine. 2019 Aug 12;14 :6465-6480. [PMID: 31616140]

2020

• Mayumi Kawabe, Koji Urano, Mayuko Suguro, Tomomi Hara, Yasushi Kageyama, Yukinori Mera, Hideki Tsutsumi.
  Establishment and Validation of an Ultra-Short-Term Skin Carcinogenicity Bioassay Using Tg-rasH2 Mice.
  Vet Pathol. 2020 Jan;57(1):192-199. [PMID: 31221040]

• Kazunori Fujiwara 1, Hiroaki Yazama 1, Ryouhei Donishi 1, Satoshi Koyama 1, Takahiro Fukuhara 1, Hiromi Takeuchi.
  Inhibitory Effects of Glucosylceramide on Tumorigenesis Induced by a Carcinogen in Mice.
  Laryngoscope. 2020 Nov;130 (11) : E593-E597. [PMID: 31808958]